揽月生物医药科技

Lanyue Bio is a Chinese biotechnology company specializing in the development of mRNA-based therapeutics and vaccines. Founded by Dr. Lin Jinhui, a former senior scientist at Moderna, the company leverages a proprietary mRNA-LNP (lipid nanoparticle) delivery platform and advanced sequence optimization technologies. Their pipeline focuses on high-demand areas including infectious disease prevention (COVID-19, RSV, Influenza) and immuno-oncology (personalized cancer vaccines). Based in the Suzhou Industrial Park (Biobay), Lanyue Bio has secured significant early-stage funding from prominent investors like Sequoia China and Hillhouse. The company aims to establish a full-stack mRNA technology chain from design to large-scale GMP manufacturing.